Arbutus provides ab-729 clinical data and ab-161 preclinical data as oral presentations at the global hepatitis summit 2023

Seven patients with chbv remain off all treatment and continue to maintain low levels of hbv dna and hbsag for at least one and half years post- ab-729 treatment

ABUS Ratings Summary

ABUS Quant Ranking